

# NEUROIMMUNOLOGY


## $\beta_2$ -adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses

Moriyama, S. *et al.* Science. 2018 Mar 2;359(6379):1056-1061.

**Speaker:** Hao Hsieh



**Commentator:** Yu-Hsiang Hsu, PhD

**Date:** November 9th, 2018






# Autonomic nervous system (ANS)



**ACh-** acetylcholine  
**NE-** norepinephrine




# Development of T cells and Innate lymphoid cells (ILC) <sup>2</sup>



**HSC**- hematopoietic stem cells  
**CLP**- common lymphoid progenitor  
**ID2**- inhibitor of DNA binding 2  
**ETP**- early T cell progenitor  
**CILCP**- common ILC progenitor  
**CHILP**- common helper ILC  
**ILCPs**- PLZF<sup>+</sup> ILC progenitors




# Innate lymphoid cell (ILC)



**Type 2 inflammation**

**Bcl11b**- B cell leukemia 11b  
**GATA-3**- GATA binding protein 3  
**AREG**- Amphiregulin  
**TSLP**- stromal lymphopoietin

# Neural Regulation of Immunity



**VIP-** Vasoactive intestinal peptide

**5HTT-** 5-hydroxytryptamine transporter

Nat Rev Immunol. 2006 Apr; 6(4): 318–328.





# Neural Regulation of ILC

## ARTICLE




doi:10.1038/nature24029

### Mucosal epithelium

### ILC2



## The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation



**NMU-** Neuromedin U  
**NMUR1-** NMU receptor 1  
**NFAT-** nuclear factor of activated T cells


Nature. 2017 Sep 14;549(7671):277-281.

The interactions between the nervous system and ILC of type 2 inflammation is still **unclear**.

Nature. 2017 Sep 21;549(7672):351-356.

# Hypothesis

Adrenergic neuron regulates ILC2 responses and type 2 inflammation after exposure to helminth infection and allergens.






# Specific aims

## Aim 1:


To investigate adrenergic receptor expression on ILC and localization of ILC2 in gut associated tissues





# ILC2 co-localize with TH<sup>+</sup> neurons in the small intestine

**Bcl11b-td Tomato** reporter mouse 



**ILC2 ➡ KLRG1<sup>+</sup>Bcl11b<sup>+</sup>CD3ε<sup>-</sup>NKp46<sup>-</sup>**

White TH- tyrosine hydroxylase

Green KLRG1- killer cell lectin-like receptor G member 1

Red Bcl11b- B cell leukemia 11b

Blue CD3ε- T-cell surface glycoprotein CD3 epsilon


Cyan NKp46- mouse CD335 (natural cytotoxicity receptor)

SI- small intestine

V- villi



S- submucosa

M- muscularis






# ILC2 co-localize with TH<sup>+</sup> neurons in the small intestine



**ILC2 → KLRG1<sup>+</sup>tdTomato<sup>+</sup>CD3ε<sup>-</sup>**

White **TH**- tyrosine hydroxylase  
 Green **KLRG1**- killer cell lectin-like receptor G member 1  
 Red **Il13**-fate mapping  
 Blue **CD3ε**- T-cell surface glycoprotein CD3 epsilon


SI- small intestine





# ILC2 were also observed in mesenteric lymph node

**Bcl11b-td Tomato** reporter mouse



**ILC2** ➔ **KLRG1<sup>+</sup>Bcl11b<sup>+</sup>CD3 $\epsilon$ <sup>-</sup>IgD<sup>-</sup>**



**Green** KLRG1- killer cell lectin-like receptor G member 1

**Red** Bcl11b- B cell leukemia 11b

**Blue** CD3 $\epsilon$ - T-cell surface glycoprotein CD3 epsilon


**Cyan** IgD

mLN- mesenteric lymph node



# Summary 1

1.  $\beta 2AR$  gene is highly expressed in murine and human ILC2 both from gut and lung tissue.
2. Murine ILC2 and adrenergic neurons ( $TH^+$ ) are in proximity in gut tissue.




**Adrb2**-  $\beta 2$  adrenergic receptor gene  
 **$\beta 2AR$** - beta 2 adrenergic receptor



# Specific aims

## Aim 2:





To clarify whether  $\beta$ 2AR signaling inhibits ILC2 responses in anti-helminth responses



$\beta$ 2AR- beta 2 adrenergic receptor








# ILC2 population and responses increased in $\beta 2AR$ -deficiency mice



*N. brasiliensis*- *Nippostrongylus brasiliensis*  
S.C.- subcutaneously  
mLN- mesenteric lymph node  
SILP- SI lamina propria

# Anti-helminth responses was enhanced in $\beta$ 2AR-deficiency mice

*Adrb2*<sup>+/+</sup> or  
*Adrb2*<sup>-/-</sup>  
C57BL/6J








PAS-Alcian blue staining

mLN- mesenteric lymph node  
SI- small intestine








# ILC2 population and responses decreased in $\beta$ 2 agonist-treated mice



**Clen-** Clenbuterol  
**mLN-** mesenteric lymph node  
**CD127-** IL-7 receptor  $\alpha$

Cells are pre-gated on Lin<sup>-</sup>CD45<sup>+</sup>

# Anti-helminth responses was attenuated in $\beta$ 2 agonist-treated mice








**Clen-** Clenbuterol  
**mLN-** mesenteric lymph node  
**SI-** small intestine

**PAS-Alcian blue staining**






# β2 agonist-mediated inhibition of ILC2 responses and inflammation occurred in the absence of CD4<sup>+</sup>T cells



**I.P.**- intraperitoneal  
**Clen**- Clenbuterol  
 **$\alpha$ -CD4**- anti CD4 monoclonal antibody  
**SI**- small intestine






# Anti-helminth responses of IL-7R<sup>+</sup> β2AR<sup>-</sup> ILC2 were enhanced




**Cre**- Cre recombinase  
**Il7r**- IL7 receptor  
**I.P.**- intraperitoneal  
 **$\alpha$ -CD4**- anti CD4 monoclonal antibody



# The inhibitory effect of $\beta$ 2AR signaling is directly on ILC2




**ILC2P-** ILC2 progenitor  
**Rag2-** Recombination activating gene 2  
**Il2rg-** IL2 receptor gamma chain



# Summary 2

1.  $\beta$ 2AR signaling negatively regulates ILC2-mediated anti-helminth responses in intestinal tissue.
2.  $\beta$ 2AR-mediated negative regulation on ILC2 is T cell independent.




$\beta$ 2AR- beta 2 adrenergic receptor



## Specific aims

### Aim 3:

To clarify whether  $\beta$ 2AR signaling inhibits ILC2 responses in lung inflammation



Lung inflammation

Allergen

IL-33

ILC2

$\beta$ 2 AR

$\beta$ 2 agonist

IL-5

Eosinophil

IL-13



mucus

Goblet cell


Type 2  
inflammation




# β2AR deficient enhanced ILC2 numbers in lung inflammation



**A**



**B**










**CD127<sup>+</sup>CD90<sup>+</sup>Lin<sup>-</sup>CD45<sup>+</sup>**

S.C.- subcutaneously  
 I.N.- intranasal  
 I.P.- intraperitoneal  
 Salm- salmeterol  
 CD127- IL-7 receptor α



# β2AR activation inhibited ILC2 responses in lung inflammation




Alternaria- Alternaria extract


I.N.- intranasal  
 I.P.- intraperitoneal  
 Salm- salmeterol  
 CD127- IL-7 receptor α




# $\beta$ 2AR signaling to reduce ILC2 responses in lung is also T cell independent



F



G




**Alternaria-** Alternaria extract  
**I.N.-** intranasal  
**I.P.-** intraperitoneal  
 **$\alpha$ -CD4-** anti CD4 monoclonal antibody



# Summary 3


1.  $\beta$ 2AR signaling dampen ILC2 responses in lung inflammation.
2.  $\beta$ 2AR-mediated negative regulation is directly on ILC2 but not through T cell pathway.



# ❄️ Specific aims

## Aim 4:


To investigate the mechanism through which  $\beta$ 2AR signaling attenuates ILC2 responses and type2 inflammation




$\beta$ 2AR- beta 2 adrenergic receptor



# β2AR signaling downregulates gene expression related to cell cycle




## GSEA (Gene set enrichment analysis)



**KLRG1+CD127+CD45+CD90+Lin- mLN ILC2 sorted from *N. brasiliensis*-infected *Adrb2*<sup>+/+</sup> mice**







**Id2**- ILCP marker  
**Gata3, Rora**- ILC2 transcription factor  
**IL1RL1**- IL-33R (ST2)  
**IL4Ra**- IL4 Receptor a chain  
**Crf2**- TSLP Receptor

**NES**- Normalized enrichment score  
**FDR**- false discovery rate










# β2AR stimulation suppressed ILC2 proliferation but dose not regulate apoptosis



**S.C.**- subcutaneously  
**I.P.**- intraperitoneal  
**H. polygyrus**- *Heligmosomoides polygyrus*



# β2AR stimulation negatively regulated ILC2-intrinsic cell proliferation *in vitro* and *in vivo*




**SILP-** SI lamina propria  
**BM-** bone marrow  
**GMFI-** geometric mean fluorescent intensity

# Summary 4

1.  $\beta$ 2AR stimulation reduce the gene expression of cell cycle.


2.  $\beta$ 2AR signaling negatively regulates ILC2-intrinsic cell proliferation *in vitro* and *in vivo*.



$\beta$ 2AR- beta 2 adrenergic receptor

# Conclusion

Adrenergic neuronal derived regulatory circuit through  $\beta$ 2AR pathway limits ILC2 proliferation and ILC2-dependent type 2 inflammation in intestinal and lung tissues.




$\beta$ 2AR- beta 2 adrenergic receptor

# Discussion 1






# Possible anti-asthma mechanism of $\beta$ 2 agonist in addition to bronchodilation






# Possible anti-asthma mechanism of $\beta$ 2 agonist in addition to bronchodilation



# Discussion 2



# The difference of $\beta$ 2 signaling in ILC2 and Th2



**$\beta$ 2 agonist**

**$\beta$ 2 agonist**

**Type 2 inflammation**

No express  $\beta$ 2 AR

Cellular immunity

Janeway's Immunobiology 9E  
 J Clin Invest. 1997 Sep 15; 100(6): 1513–1519.  
 Nature review poster Dendritic cells: controllers of adaptive immunity



**THANK YOU**



# Clenbuterol

In the U.S., clenbuterol is **not approved for human use** it is only approved for use in horses.

## Side effect:

cardiovascular and neurological effects

**Retrieve palpitations, muscle tremors, and nervousness.**

exhibits were identified ability to increase lean muscle mass and reduce body fat, although the downstream mechanisms

After ingestion, clenbuterol is readily absorbed (70-80%) and remains in the body for awhile (**25-39 hours**).

As a result of its **long half life**, the adverse effects of clenbuterol are often prolonged



# Asthma animal model

*Alternaria alternata*

Balb/c


i.p.  $2 \times 10^6$  spores in Alum

i.n.  $2 \times 10^5$  spores 1/d for 3d  
(d13-15)

Increased lymphocytes, eosinophilic & neutrophilic inflammation

Increased IgE, IgG<sub>1</sub> [78]


Med Mycol. 2010 Mar;48(2):217-28







# Steps in the biosynthesis of the catecholamines

**AUTONOMIC NS**  
**Parasympathetic**  
**division**





**Sympathetic**  
**division**



Vander's Human Physiology-14e

Brody's Human Pharmacology 5e





**Rearrangement**

D to J <sub>β</sub>	CD44 <sup>+</sup> CD25 <sup>-</sup> to CD44 <sup>-</sup> CD25 <sup>-</sup>
V to DJ <sub>β</sub>	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>
V to J <sub>α</sub>	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>-</sup> CD25 <sup>-</sup>
V to J <sub>γ</sub> and V to DJ <sub>δ</sub>	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>

**Transcription factor**

TCF1	CD44 <sup>+</sup> CD25 <sup>-</sup> to CD44 <sup>-</sup> CD25 <sup>-</sup>
GATA3	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>
Bcl11b	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>
KLF2	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>
ThPOK	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>
Runx3	CD44 <sup>+</sup> CD25 <sup>+</sup> to CD44 <sup>low</sup> CD25 <sup>+</sup>

Protein	Function	Expression
Kit	Signaling	CD44 <sup>+</sup> CD25 <sup>-</sup>
Notch	Signaling	CD44 <sup>+</sup> CD25 <sup>+</sup>
pTα	Surrogate α chain	CD44 <sup>+</sup> CD25 <sup>+</sup>
CD3	Signaling	CD44 <sup>low</sup> CD25 <sup>+</sup>
CD4	Co-receptor	CD44 <sup>low</sup> CD25 <sup>+</sup> to CD44 <sup>-</sup> CD25 <sup>-</sup>
CD8		CD44 <sup>low</sup> CD25 <sup>+</sup> to CD44 <sup>-</sup> CD25 <sup>-</sup>
IL-7R	Signaling	CD44 <sup>+</sup> CD25 <sup>+</sup>
ZAP-70	Signal transduction	CD44 <sup>low</sup> CD25 <sup>+</sup>
Syk		CD44 <sup>low</sup> CD25 <sup>+</sup>
Lck		CD44 <sup>low</sup> CD25 <sup>+</sup>
Fyn		CD44 <sup>low</sup> CD25 <sup>+</sup>
CD2		CD44 <sup>low</sup> CD25 <sup>+</sup>
RAG-1/2	Lymphoid-specific recombinase	CD44 <sup>+</sup> CD25 <sup>+</sup>
TdT	N-nucleotide addition	CD44 <sup>+</sup> CD25 <sup>+</sup>

either CD4 or CD8



# ILC markers

Table 1 | Phenotypical markers of mouse ILC subsets

Marker	Group 1 ILCs		Group 2 ILCs			Group 3 ILCs		
	NK cells	ILC1s	ILC2s (natural helper cells)	ILC2s (nuocytes)	ILC2s (I <sub>H</sub> 2 cells)	LTi cells	NCR <sup>+</sup> ILC3s*	Colitogenic NCR <sup>-</sup> ILC3s
CD4	-	-	-	-	-	+	10%	-
CD25	+ <sup>‡</sup>	low	+	+	+	+(75%)	ND	+
CD90 (also known as THY1)	-/+ <sup>§</sup>	ND	+	+	+	+	+	+
CD117 (also known as KIT)	-	-	+	+	+	+	+	-
CD127 (also known as IL-7R $\alpha$ )	-/+ <sup>§</sup>	+	+	+	+	+	+	+
SCA1 (also known as LY6A)	+ <sup>‡</sup>	ND	+	+	+	-	ND	+
ICOS	low <sup>  </sup>	ND	ND	+	+	ND	- <sup>  </sup>	ND
NKp46 (also known as NCR1)	+	-	-	-	-	-	+	-
IL-1R	-	+	- <sup>  </sup>	ND	ND	+	+	+
IL-23R	-	-	ND	ND	ND	+	+	+
IL-12R $\beta$ 2	+	+	-	-	-	-	-	-
ST2 (a subunit of IL-33R)	-	-	+	+	+	-	ND	ND
IL-17RB (a subunit of IL-25R)	-	-	+	+	+	-	-	-

ICOS, inducible T cell co-stimulator; I<sub>H</sub>2, innate helper 2; IL, interleukin; ILC, innate lymphoid cell; LTi, lymphoid tissue-inducer; NCR, natural cytotoxicity triggering receptor; ND, not determined; NK, natural killer; SCA1, stem cell antigen 1. \*Also referred to as NK22 cells, NCR22 cells, NKR-LTi cells and ILC22s. <sup>‡</sup>Following activation. <sup>§</sup>On subset of cells. <sup>||</sup>As determined by microarray analysis; natural helper cells do not respond to IL-1 $\beta$ .






# ILC markers

Table 2 | **Phenotypical markers of human ILC subsets**

Marker	Group 1 ILCs		Group 2 ILCs	Group 3 ILCs	
	NK cells	ILC1s	ILC2s	LTi cells	NCR <sup>+</sup> ILC3s*
CD4	–	–	–	–	–
CD25	–/+ <sup>‡</sup>	low	low	ND	low
CD56	+	–	ND	–	50%
CD117 (also known as KIT)	–	–	+/-	+	+
CD127 (also known as IL-7R $\alpha$ )	–/+ <sup>§</sup>	+	+	+	+
CD161	–/+ <sup>§</sup>	+/-	+	+/-	+
NKp44 (also known as NCR2)	–/+ <sup>  </sup>	–	–	–	+
ICOS	low	+	+	ND	+
NKp46 (also known as NCR1)	+	–	–	–	+
CRTH2	–	–	+	–	–
IL-1R	–	+	+	+	+
IL-23R	–	–	ND	+	+
IL-12R $\beta$ 2	+	+	–	–	–
ST2 (a subunit of IL-33R)	–	–	+	–	–
IL-17RB (a subunit of IL-25R)	–	–	+	–	–



# ILC markers

	Group 1		Group 2		Group 3	
						
Cell lineage	ILC1	NK	ILC2	ILC3	LTi	
Surface markers	LIN <sup>-</sup>	NKG2D <sup>+</sup>	LIN <sup>-</sup>	LIN <sup>-</sup>	LIN <sup>-</sup>	
	CD45 <sup>+</sup>	CD45 <sup>+</sup>	CD45 <sup>high</sup>	CD45 <sup>+</sup>	CD45 <sup>int</sup>	
	IL-7Rα <sup>-</sup>	CD122 <sup>+</sup>	IL-7Rα <sup>+</sup>	IL-7Rα <sup>+</sup>	IL-7Rα <sup>high</sup>	
	CD56 <sup>+</sup>	CD56 <sup>+</sup>	CD56 <sup>-</sup>	CD56 <sup>+</sup>	CD7 <sup>+</sup>	
	NKp30 <sup>+</sup>	KIR <sup>+</sup>	CRTH2 <sup>+</sup>	NKp30 <sup>+</sup>	CD94	
	NKp44 <sup>+</sup>	CD161 <sup>+</sup>	CD161 <sup>+</sup>	NKp44 <sup>+</sup>	CD161 <sup>+</sup>	
Key regulators	Tbet	E4BP4	RORα	RORγt	RORγt	
Cytokine signature	IFN-γ	IFN-γ TNF	IL-4, 5, 13 IL-6, 9	IL-22	IL-17A, 22 LTα, LTβ	
Immune association	Crohn's disease	Tumour surveillance	Asthma AD	Asthma, psoriasis	Homeostasis, organogenesis	

ILC, innate lymphoid cell; NK, natural killer; LTi, lymphoid tissue inducer; LIN<sup>-</sup> lineage negative (CD3, CD4, CD8 CD19, CD11b, CD11c, CD123, CD14, FcεR1, T-cell receptor (TCR)γδ, TCRαβ; NKG2D, natural killer group 2, member D; IL-7Rα, interleukin-7 receptor alpha; KIR, killer cell immunoglobulin-like receptor; CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; Tbet, T box expressed in T cells; ROR, retinoic acid receptor-related orphan receptor; IFN, interferon; TNF, tumour necrosis factor; LT, lymphotoxin; AD, atopic dermatitis.


**CD25-** activated T, B cell, ILC, monocyte  
**=IL-2Rα**  
**CD45-** all hematopoietic cell  
 =Leukocyte common antigen (**LCA**)  
 Tyrosine phosphatase T,B cell antigen receptor  
**CD90-** T cell(mouse), ILC, NK  
**=Thy-1**  
**Adhesion trafficking**



# ILC markers

**Table 1. Main Phenotypic Markers of the Different Subsets of Murine and Human ILCs**

		Mouse						Human						
		NK	ILC1	ILC2	LTi	NKp46 <sup>-</sup> ILC3	NKp46 <sup>+</sup> ILC3	NK	ILC1	ILC2	LTi	NKp44 <sup>-</sup> ILC3	NKp44 <sup>+</sup> ILC3	
Cell-surface molecules	CD45	+	+	+	int	+	+	CD45	+	+	++	int	+	+
	CD127 (IL-7Ra)	<sup>a</sup>	<sup>b</sup>	+	++	W	W	CD127 (IL-7Ra)	-/+	<sup>e</sup>	+	+	+	+
	CD161 (NK1.1)	+	+	-	-	-	-/+	CD161 (NK1.1)	+/-	+	+	+/-	+	+
	ST2 (IL-33R)	-	nd	+/-	nd	nd	nd	ST2 (IL-33R)	+/-	-	+/-	nd	nd	-
	CD278 (ICOS)	W	nd	++	nd	W	W	CD278 (ICOS)	-	nd	+	nd	nd	+
	IL-17Rβ (IL25R)	-	nd	+	-	-	-	IL-17Rβ (IL25R)	-	-	+	-	nd	-
	CD294 (CRTH2)	-	nd	+	nd	nd	nd	CD294 (CRTH2)	-	-	+	-	-	-
	KLRG1	++	-	+	-	-	-	KLRG1	+	-	+	-	-	-
	CD117 (c-kit)	-	+/-	+/-	++	W	W	CD117 (c-kit)	-/W	-	+/-	+	+	+
	CD69	<sup>c</sup>	+	nd	nd	nd	nd	CD69	W	+/-	nd	nd	nd	nd
	CD254 (RANKL)	nd	nd	nd	+	+	+	CD254 (RANKL)	-	nd	nd	+	+	+
	CD196 (CCR6)	-	nd	-	+	+/-	-	CD196 (CCR6)	-	+/-	+/-	+	+/-	+/-
	CD335 (NKp46)	+	+	-	-	-	+	CD335 (NKp46)	+	-	-	-	-/W	W/+
	CD25 (IL-2Rα)	<sup>d</sup>	-/W	+	+/-	+/-	+/-	CD25 (IL-2Rα)	+/-	W	+	W	+/-	-/W
	MHC-II	-	-	+	+	+	-	MHC-II	+/-	nd	+/-	nd	nd	+/-
	IL23R	-	-	nd	+	+	+	IL23R	+/-	+/-	-/W	+	+	+
	IL1Rβ	-	+	nd	+	+	+	IL1R	+/-	+	W	+	+	+
	CD122	+	+	W	-	-	-	CD122	+	nd	nd	-/W	W	W
	CD314 (NKG2D)	+	nd	-	-	-	+	CD314 (NKG2D)	+	nd	nd	-	-W	-/W
	Ly49	+/-	+/-	-	-	-	-	KIR	+/-	-	-	-	-	-
	CD94	+/-	nd	+/-	nd	-	+/-	CD94	+/-	-	-	-	-	-
	Perforin	+	W	-	-	-	-	Perforin	+	-	-	-	-	-
	CD253 (TRAIL)	-	+	nd	nd	nd	nd	IL12Rβ	+	+	-	-	-	+/-
	Sca-1 (Ly6a)	<sup>d</sup>	+	+	-	nd	+	CD194 (CCR4)	nd	+/-	+	nd	nd	nd
	CD49d (integrin α4β7)	nd	nd	-	nd	+	+	CD56	+	-	-	-/W	+/-	+/-
	CD49a (integrin α1β1)	<sup>a</sup>	+	nd	nd	nd	nd	CD183 (CXCR3)	nd	+	nd	nd	nd	nd
	CD90 (Thy1)	+/-	+	+	+	+	+	CD337 (NKp30)	+	+	+	+/-	+/-	+/-
CD160	<sup>f</sup>	+	nd	nd	nd	nd	CD336 (NKp44)	<sup>d</sup>	-	-	-	-	+	
CD103	<sup>g</sup>	-	nd	nd	nd	nd	CD16	+/-	-	-	-	-	-	
CD200R	-	+	nd	nd	nd	nd	NKp80	+	-	nd	nd	nd	nd	
Transcription factors	Tbet	+	+	-	-	+/-	+	Tbet	+	+	-	-	-	-
	Eomes	+	+/-	-	-	-	-	Eomes	+	+/-	-	-	-	-
	RORγt	-	-	-	+	+	+	RORγt	-	-/W	-/W	+	+	+
	GATA3	-/W	-/W	+	-/W	-/W	-/W	GATA3	-/W	-/W	+	-/W	-/W	-/W
	AhR	-	nd	nd	+	+	+	AhR	-/W	W	+	+	+	+
	RORα	nd	nd	+	nd	nd	nd							



Cre- Cre recombinase

# GESA

